Dror Harats

Tel Aviv University — Israel

Immunology and Microbiology · Life Sciences

52h-index9.3kcitations283works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Atherosclerosis and Cardiovascular Diseases(64), Antioxidant Activity and Oxidative Stress(31), Lipoproteins and Cardiovascular Health(29), Adipokines, Inflammation, and Metabolic Diseases(26), Glioma Diagnosis and Treatment(25)

Publications282 total

Supplementary Data 1 from Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma
2025Open Access
Supplemental Figure S1 from Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma
2025Open Access
Supplemental Figure S2 from Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma
2025Open Access
Factor XI Deficiency in apoE/FXI Double-Knockout Mice Decreases Atherosclerosis by Lowering <i>MSR1</i> mRNA Expression Within the Plaque
Journal of Lipid and Atherosclerosis·2025Open Access
Supplementary Data 1 from Depth of radiographic response (DpR) and time to tumor regrowth (TTG) predicts overall survival following anti-VEGF therapy in recurrent glioblastoma
2024Open Access
Supplemental Figure S1 from Depth of radiographic response (DpR) and time to tumor regrowth (TTG) predicts overall survival following anti-VEGF therapy in recurrent glioblastoma
2024Open Access
Supplemental Figure S2 from Depth of radiographic response (DpR) and time to tumor regrowth (TTG) predicts overall survival following anti-VEGF therapy in recurrent glioblastoma
2024Open Access
Data from Depth of radiographic response (DpR) and time to tumor regrowth (TTG) predicts overall survival following anti-VEGF therapy in recurrent glioblastoma
2024Open Access
Supplemental Figure S2 from Depth of radiographic response (DpR) and time to tumor regrowth (TTG) predicts overall survival following anti-VEGF therapy in recurrent glioblastoma
2024Open Access
Supplementary Data 1 from Depth of radiographic response (DpR) and time to tumor regrowth (TTG) predicts overall survival following anti-VEGF therapy in recurrent glioblastoma
2024Open Access
Supplemental Figure S1 from Depth of radiographic response (DpR) and time to tumor regrowth (TTG) predicts overall survival following anti-VEGF therapy in recurrent glioblastoma
2024Open Access
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018)
Journal of Clinical Oncology·2023· 19 cited
Supplemental Figure S1 from Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma
2023Open Access
Supplemental Figure S2 from Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma
2023Open Access
Supplemental Figure S1 from Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma
2023Open Access
Data from Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma
2023Open Access
Supplementary Data 1 from Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma
2023Open Access
Supplementary Data 1 from Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma
2023Open Access
Data from Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma
2023Open Access
Supplemental Figure S2 from Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma
2023Open Access
page 1 of 15Next →

Frequent Co-authors

Aviv Shaish(22), Jacob George(20), Yehuda Shoenfeld(17), Arnon Afek(14), Boris Gilburd(13), Hana Levkovitz(9), Yehuda Kamari(8), Juri Kopolovic(7), Iris Goldberg(5), Hofit Cohen(5), Ayelet Harari(5), Iris Barshack(4), Y. Stein(4), Ayelet Gonen(4), Charles A. Dinarello(3), Ron N. Apte(3), Miri Blank(3), Yair Levy(3), Pnina Keren(3), M. Ben-Naim(3)